Epitumomab is a novel, promising therapeutic antibody that targets MS4A1, a key protein expressed on the surface of B-cells. By selectively targeting MS4A1, it offers a mechanism of action that allows for more precise treatment with fewer side effects compared to traditional therapies. With increasing interest in precision medicine and immunotherapy, Epitumomab is emerging as a strong candidate for addressing various B-cell malignancies, including those affecting the immune system, such as lymphoma and leukemia.